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Abstract
Background: The aim of this prospective observational study was to compare peri/post-operative
outcomes of thoracic epidural analgesia (TEA) versus intrathecal morphine and fentanyl patient-controlled
analgesia (ITM+fPCA) for patients undergoing a hepatic resection (HR).
Method: Patients undergoing elective, one-stage, open HR for benign and malignant liver lesions,
receiving central neuraxial block as part of the anaesthetic, in a high-volume hepato-pancreato-biliary
unit, were included in the study. The primary outcome measure was post-operative length of stay (LoS).
Results: A total of 73 patients (36 TEA and 37 ITM+fPCA) were included in the study. The median (IQR)
post-operative LoS was 13 (11–15) and 11 (9–13) days in the TEA and ITM+fPCA groups, respectively
(P = 0.011). There was significantly lower median intra-operative central venous pressure (P < 0.001) and
blood loss (P = 0.017) in the TEA group, and a significant reduction in the time until mobilization (P <
0.001), post-operative intra-venous fluid/vasopressor requirement (P < 0.001/P = 0.004) in the ITM+fPCA
group. Pain scores were lower at a clinically significant level 12 h post-operatively in the TEA group (P <
0.001); otherwise there were no differences out to day five. There were no differences in quality of recovery
or postoperative morbidity/mortality between the two groups.
Conclusion: ITM+fPCA provides acceptable post-operative outcomes for HR, but may also increase the
incidence of intra-operative blood loss in comparison to TEA.
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Introduction
A hepatic resection (HR) offers a potential cure for patients with
colorectal liver metastases with 5-year survival rates of approxi-
mately 30–40%1 and cure rates of 16% at 10 years.2 Advances in
surgical technique and peri-operative care enable a safe resection
of up to 70% of functional liver parenchyma, including multifocal
metastases, and has an associated in-hospital mortality of 5% or
less.3,4
The success of peri-operative care programmes is dependent
on optimal analgesia, which can modulate the stress response to
surgery and improve post-operative outcomes.5,6 Thoracic epi-
dural analgesia (TEA) is often considered the gold standard
analgesic modality for major intra-abdominal surgery as it pro-
vides better analgesia than the common alternative of intra-
venous opioids and results in less respiratory complications.7,8
However, a disadvantage of TEA includes sympathetic block
leading to hypotension in the post-operative period. This is often
treated with excessive fluid administration that can lead to
increases in blood product transfusion rates, delayed mobiliza-
tion and increased hospital length of stay (LoS).9–12 TEA also has
a high failure rate and requires greater resources including spe-
cialized nursing care.13,14 To date, TEA is the main mode of anal-
gesia in most peri-operative care programmes for patients
undergoing HR, including those utilizing enhanced recovery
protocols.15–17
Intrathecal opioid has been reported as an alternative to TEA,
offering equivalent analgesia, for patients undergoing HR.18,19
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When intrathecal opioid has been compared with TEA in
colorectal surgery, it has been shown to improve outcomes includ-
ing decreased post-operative morbidity, reduced resource alloca-
tion and shorter LoS.20,21
The aim of this study was to determine differences in peri/post-
operative outcomes of patients receiving TEA versus intrathecal
morphine and fentanyl patient-controlled analgesia (ITM+fPCA)
for patients undergoing HR.
Methods
A prospective, single centre, observational study was conducted
for all patients undergoing HR in a high-volume hepato-
pancreato-biliary (HPB) surgical unit (Royal Free London NHS
Foundation Trust, University College, London), between August
2012 and June 2013. The study was approved by the local institu-
tional review board.
Patients undergoing an elective, one-stage, open hepatic resec-
tion for benign and malignant liver lesions receiving central
neuraxial blocks (CNB) as part of their anaesthetic were included
in the study. Patients were excluded if they had pre-existing
chronic pain, opioid dependence, pre-operative mechanical assis-
tance for mobility, alternative laparotomy incisions other than
inverted ‘L’ incisions, a laparoscopic/hand-assisted laparoscopic
operation or extended post-operative ventilation beyond 12 h. A
total of five consultant HPB surgeons and seven consultant anaes-
thetists were directly involved in the peri-operative care of the
patients.
Peri-operative care
All CNBs were performed with the patient awake, before induc-
tion of general analgesia, in the sitting position and with an
aseptic technique. Further information regarding the CNB
technique/dosage and the remainder of the anaesthetic is pro-
vided in Supporting Information 1. Weaning of the epidurals in
the TEA group was commenced on post-operative day (POD)
three with an aim of cessation by POD four. In the intra-thecal
morphine group, fPCA was commenced post-operatively at a
bolus dose of 25 mcg with a 5-min lockout with an aim for ces-
sation by POD four.
Patients in the TEA group who required intra-venous opioid
to achieve satisfactory pain relief in the presence of a non-
recoverable inadequate sensory block (assessed by the acute pain
team or duty anaesthetist) were deemed to have ‘failed TEA’. The
epidurals in these patients were stopped and analgesia was con-
verted to fPCA or rescue intra-venous opioids.
In addition to CNB, all patients were given regular oral para-
cetamol (1 g) and tramadol (50 mg) in the post-operative period,
at intervals of 6 h. Patients were also prescribed intra-venous
ondansetron at a dose of 4 mg twice daily for anti-emesis. Those
requiring additional anti-emetics were given cyclizine (50 mg), up
to three times daily, on an as required basis.
After the surgery, all patients were transferred to the intensive
care unit for a minimum of 12 h and then to a specialized HPB
ward where they received standardized care (Supporting Informa-
tion 2).
Operative technique
HR was performed using the Cavitron Ultrasonic Surgical Aspi-
rator (CUSA; Valleylab, CO, USA) and Argon beam coagulation.
For patients with malignant tumours, the transection plane was
first determined by intra-operative ultrasonography. The inflow
and outflow vessels supplying the sectors to be resected were
divided by stapling or ligated with a running polypropylene
suture. Inflow occlusion (Pringle manoeuvre) was used when
deemed necessary to control on-going blood loss during paren-
chymal division at the discretion of the consultant surgeon. When
utilized, inflow occlusion was used in periods of up to 20 min with
a 3–5 min recovery. In some instances the raw surface of the
liver remnant was sealed with TachoSil (Nycomed, Zurich,
Switzerland).
Clinical outcomes
Patient demographics [age, gender, body mass index (BMI),
American society of anaesthesiologists (ASA) score, predicted
morbidity and mortality] and pre-operative variables (aetiology
of liver disease, chemotherapy status, presence of liver cirrhosis
and type of HR) were recorded for all patients. The predicted risk
of morbidity and mortality was calculated using a risk prediction
model based on the Portsmouth physiological and operative
severity score for the enumeration of mortality and morbidity
(P-POSSUM).22 The type of HR was determined according to the
number of segments resected (minor < 3 or major >3).
The primary clinical outcome was post-operative LoS and was
measured from the date and start time of surgery to the date and
time of discharge. Patients were deemed to be medically fit for
discharge when they met the following discharge criteria: good
pain control with oral analgesia, resumption of a normal diet,
independent mobility, normalizing liver function and no unre-
solved medical or surgical complications requiring further
treatment.
Secondary clinical outcomes included intra-operative blood
loss/packed red blood cell (PRBC) transfusion/Pringle manoeuvre
outcomes/central venous pressure (CVP) measurements/operative
time, post-operative intravenous fluids (IVF) requirement/blood
product transfusion/vasopressor requirement, time delay until
intake of fluids/intake of solids/removal of catheter/mobilisation/
medically fit for discharge, cumulative opioid requirements, pain
scores, morbidity, mortality and quality of recovery (QoR). Pain
scores were measured using a visual analogue scale (VAS) ranging
from 0 to 100 mm at 12-h intervals up to 96 h post-operatively.23
Cumulative opioid requirements were calculated for the first 4
post-operative days (total opioid administered was converted to
equivalent fentanyl dose in micrograms). Surgical complications
were graded up to 30 days post-operatively in accordance to the
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Clavien–Dindo classification.24 Patients were asked to complete a
validated QoR questionnaire25 at a pre-assessment clinic, POD
three and five.
Statistical analysis
Statistical analysis was performed using SPSS version 20 (SPSS,
Chicago, IL, USA). A P-value of < 0.05 was used to define statis-
tical significance. Mann–Whitney U-test and Chi-squared test
were used to compare continuous and categorical variables,
respectively.
Results
A total of 96 patients were identified in the study period. After
application of the exclusion criteria, 73 patients (76%), consisting
of 36 with TEA and 37 with ITM+fPCA were included in the final
analysis (Fig. 1). No differences were observed in the ratio of
patients receiving TEA versus ITM+fPCA in the first (1.3), second
(0.9), third (1.1) and fourth (0.7) quartiles of the study time
period (P = 0.823). There were also no differences observed in the
ratio of patients receiving TEA versus ITM+fPCA by the seven
anaesthetists (0.6, 0.8, 1.2, 0.9, 1.5, 0.8, 0.6, P = 0.918) and five
surgeons (1, 0.6, 1, 0.9, 1.4, P = 0.867). Patient demographics and
pre-operative variables are demonstrated in Table 1.
The median (IQR) post-operative LoS was 13 (11–15) and 11
(9–13) days in the TEA and ITM+fPCA groups, respectively (P =
0.011). After excluding patients with failed TEA (n = 7), the
median (IQR) post-operative LoS remained the same at 13 (11–
15) days (P = 0.015). The median (IQR) time until medically fit
for discharge was 12 (10–14) and 10 (8–12) days in the TEA and
ITM+fPCA groups, respectively (P = 0.007).
The trend of CVP at baseline, pre-resection and the median of
multiple readings taken during the resection phase are demon-
strated in Fig. 2. Post-operative variables and outcomes are shown
in Table 2.
Morbidity and mortality
Post-operative morbidity outcomes of the TEA and ITM+fPCA
groups are demonstrated in Table 3. There were no immediate or
delayed complications of TEA or ITM placement and no evidence
of neurological sequelae up to 30 days post-operatively. One
patient in the TEA group required re-operation 4 h post-
operatively for bleeding, and a further patient in the ITM+PCA
group required closure of an abdominal wound dehiscence on
POD 6. There were two episodes of respiratory depression requir-
ing medical intervention, both in the TEA group, in patients who
had ‘failed epidurals’ requiring rescue intravenous opioid. One
patient required naloxone and the other supplemental oxygen for
treatment. Two patients were readmitted to hospital, one in the
TEA group for a superficial wound infection on POD 12, and the
other in the ITM+fPCA group with a deep vein thrombosis on
POD 14. They received routine treatment and had no long-term
complications. There was no 30-day mortality in either group.
Visual analogue scale pain scores
Outcomes of VAS pain scores at varying time points for all
patients included in the study, grouped as per initial mode of
CNB, are demonstrated in Fig. 3. The median (IQR)/mean (SD)
cumulative intra-venous opioid use in the first 4 PODs was 0
(0-0)/ 119 (263) and 500 (473–550)/ 532 (130) mcg of fentanyl in
the TEA and ITM+fPCA group, respectively (P < 0.001).
Quality of recovery scores
The median (IQR) QoR scores in the TEA versus ITM+fPCA
group was 115 (109–138) vs. 113 (107–134) pre-operatively (P =
0.321), 98 (85–102) vs. 90 (83–102) on POD 3 (P = 0.482), and 91
(81–101) vs. 87 (82–98) on POD 5 (P = 0.343).
Discussion
This study has shown that patients receiving ITM+fPCA have a
significantly shorter post-operative LoS than those receiving TEA.
Patients receiving ITM+fPCA also had significantly less post-
operative intra-venous fluid administration, vasopressor require-
ment and an earlier time to independent mobilization. Apart from
12 h post-operatively there were no clinically significant differ-
ences in pain scores between patients having ITM+fPCA or TEA.
There were also no differences in post-operative morbidity scores,
defined morbidities and quality of recovery. Patients receiving
TEA did however have a shorter operative duration and a signifi-
cantly lower intra-operative blood loss.
The shorter post-operative LoS in the ITM+fPCA group has
also been previously demonstrated by two retrospective studies of
HR showing reductions of 2.1 and 4.5 days in comparisons to
patients receiving TEA.19,26 Reduced post-operative LoS may be
accounted for by the significantly improved time until mobiliza-
tion. However, the median post-operative LoS for patients in this
study is higher than some modern day high-volume HPB centres,
which report figures of between 3–6 days.15–17 These improved
outcomes are associated with the use of enhanced recover after
surgery (ERAS) programmes, which are currently being imple-
mented in the study institution. The results of this study are
therefore limited in the context of ERAS.
Patients having TEA had a shorter operating time then those
having ITM+fPCA by a median of 57 min. There was also signifi-
cantly more blood loss in the ITM+fPCA group, possibly suggest-
ing more challenging and thus longer surgery. Although not
statistically significant the ITM+fPCA group was also more likely
to have hepatic inflow occlusion to reduce bleeding. An explana-
tion for this may be the ability of TEA to reduce CVP and conse-
quently decrease venous congestion and bleeding during the
resection phase of the operation.27,28 This is supported by the
findings of significantly lower CVP in the TEA group, at the start
and during the resection phase of the operation.
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Total number of hepatic
resections in study period
n=96
Total number of open
operative cases eligible for
study
n=81
Excluded cases:
•  Patient declined CNB
    (n=2)
•  CNB contra-indicated due
    to coagulopathy (n=1)
Total number of cases
receiving CNB
n=78
ITM+PCA
n=38*
ITM+PCA
n=37
TEA
n=40
TEA
n=36
    Failed TEA
          n=7
•  Converted to
    fPCA (n=5)
•  Bolus does of i.v.
   opioids (n=2)
Effective TEA
n=29
Excluded cases:
•  >12 h post-operative
   ventilation (n=4)
Excluded cases:
•  >12 h post-operative
   ventilation (n=1)
INCLUDED IN
FINAL ANALYSIS
Excluded cases:
•  Laparoscopic (n=2)
•  ALLPS (n=6)
•  Midline laparotomy
   incisions (n=4)
•  Open and close non-
•  operable disease (n=3)
Figure 1 Flow of patients throughout the study. *Including three patients who had initial failed attempts at placement of TEA. ALLPS;
associating liver partition with portal vein ligation for staged hepatectomy; CNB, central neuraxial block; TEA, thoracic epidural analgesia;
ITM+fPCA, intra-thecal morphine and fentanyl patient controlled analgesia; fPCA, fentanyl patient controlled analgesia
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Patients in the ITM+fPCA group received approximately 2 litres
less intra-venous fluid than their TEA counterparts during the post-
operative period. Although not statistically significant, the ITM+
fPCA group also received less post-operative blood product transfu-
sion. These findings are consistent with previous reports comparing
intravenous fluid administration for patients having TEA to alterna-
tive methods of analgesia such ITM or PCA.11,19,20,26 Increased fluid
administration is thought to be a response to the increased incidence
of hypotension caused by the sympathetic blockade with TEA,11,26
which is also responsible for the increased post-operative vasopres-
sor requirement within this group of patients.
There was a clinically significant difference in pain scores at
12 h post-operatively, favouring the TEA group. Although pain
scores were also statistically lower 24 h post-operatively in the
TEA group, there was only a mean difference of 9 mm. The
minimum clinically significant change in patient pain severity
measured with a 100-mm VAS is considered to be 10 mm.29 No
differences in VAS were observed between 36 and 96 h. In spite of
demonstrating a better pain profile in the first 12 h, the TEA
group had similar outcomes after this interval, which was reflected
in similar outcomes of patient experience, as demonstrated by
comparable QoR scores.
Table 1 Patient demographics, pre-operative variables and intra-operative outcomes
TEA ITM+fPCA Pc
n = 36 n = 37
Age (years)a 58 (50–64) 61 (58–69) 0.118d
Gender ratio (M : F) 11:25 17:20 0.176
Body mass index (kg/m2)a 25.5 (23.2–27.3) 24.5 (22.7–26.8) 0.275d
ASA score 0.788
1 2 2
2 27 30
3 7 5
4 0 0
Predicted Morbidity-POSSUM (%)a 43.4 (31.8–64.0) 58.9 (31.8–66.5) 0.282d
Predicted Mortality-POSSUM (%)a 2.2 (1.2–4.3) 2.3 (1.2–4.4) 0.326d
Aetiology of liver disease 0.221
Colorectal liver metastases 27 34
HCC 5 2
Cholangiocarcinoma 2 0
Benign tumour 2 1
Neo-adjuvant chemotherapy 12 14 0.688
Cirrhosis 4 6 0.526
Type of resection 0.665
Minor 26 25
Major 10 12
Pringle manoeuvre 13 19 0.180
Pringle time (min)a 12.0 (10.0–15.0) 12 (11.5–15.0) 0.779
Intra-operative blood loss (ml) 0.017
≤500 29 20
501–1000 4 16
1001–2000 2 1
>2000 1 0
Intra-operative transfusion of PRBC (SU)a,b 0 (0-0)/0.7 (2.1) 0 (0–2)/0.8 (1.0) 0.066d
Intra-operative time (min)a 266 (200–362) 323 (254–401) 0.062d
aValues are median (IQR).
bValues are mean (SD) otherwise absolute numbers.
cχ2 test, except
dthe Mann–Whitney U-test.
PRBC, packed red cells; SU, standard unit; HCC, hepatocellular carcinoma.
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The limitations of this study include the lack of randomization
of patients into the defined interventional groups. Furthermore,
the outcomes of this observational study are of a single centre,
raising the question of outcome reproducibility. In spite of these
limitations, the data collection was prospective in nature and con-
ducted by a clinician not involved in post-operative patient care.
All patients had standardized analgesia regimes and post-
operative care pathways, reducing the introduction of bias from
other confounding variables.
Table 2 Post-operative outcomes
TEA ITM+fPCA Pc
n = 36 n = 37
Volume of fluid/blood products administered post-operatively (litres/SU)
Crystalloida 4.0 (3.5–4.9) 2.5 (2-0-2.5) <0.001
Colloida 0.5 (0.5–0.9) 0.5 (0–500) 0.064
Total IVFa 4.5 (4.0–5.5) 2.5 (2.3–3.0) <0.001
PRBCa,b 0 (0–2)/0.9 (1.5) 0 (0-0)/0.5 (1.3) 0.089
Other blood productsa,b 0 (0-0)/0.1 (0.5) 0 (0-0)/0 0.064
Vasopressor requirement 30 19 0.004d
Total time of post-operative inotropic requirements (h) a 8 (6–10) 5 (4–9) 0.012
Post-operative delay until tolerating clear fluids (h) a 6 (3–11) 8 (5–12) 0.404
Post-operative delay until tolerating solids (h) a 31 (12–39) 31 (24–39) 0.942
Post-operative time until removal of urinary catheter (h) a 42 (32–72) 39 (32–82) 0.811
Post-operative time until independent mobilisations (h) a 49 (40–64) 34 (28–45) <0.001
aValues are median (IQR).
bValues are mean (SD), otherwise absolute numbers.
cMann–Whitney U-test, except
dχ2 test.
IVF, intra-venous fluid; PRBC, packed red cells; SU, standard unit.
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Figure 2 Comparison of intra-operative central venous pressure
(CVP) measurements between thoracic epidural analgesia (TEA) and
intrathecal morphine and fentanyl patient-controlled analgesia
(ITM+fPCA). CVPmeasurements compared between types of central
neuraxial block (CNB) at different time points using the Mann–
Whitney U-test, *P < 0.001. Error bars indicate 95% confidence
intervals
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Figure 3 Visual analogue scale scores (VAS) of post-operative pain
on coughing, comparing thoracic epidural analgesia (TEA) and
intrathecal morphine and fentanyl patient-controlled analgesia
(ITM+fPCA) for hepatic resection surgery. VAS scores compared
between type of central neuraxial block (CNB) at different time
points post-operatively, with the Mann–Whitney U-test *P < 0.001,
**P = 0.010. Error bars indicate 95% confidence intervals
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In conclusion, this study demonstrates that ITM+fPCA pro-
vides acceptable post-operative outcomes for HR and may be a
feasible alternative to TEA, but may cause a comparative increase
in the incidence of intra-operative blood loss.
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